Quidel Corp is an American biopharmaceutical company based in San Diego, California. It is engaged in the discovery, development, manufacture, and marketing of diagnostic healthcare products that are distributed to a worldwide customer base. The company has an administrative office in China as well as manufacturing, research, and development facilities across the US, Germany, and Ireland. The firm has been in operation since 1979 and brought its first products to market in 1983.
The organisation has a strong focus on immunoassay development, monoclonal antibody characterisation and development, automated manufacturing, and molecular assay development. The firm’s products span a few diagnostic categories including lateral flow tests, direct fluorescent antibodies (DFA) micro-titer production products, fluorescent immunoassay products, and molecular diagnostic products. The firm produced the world’s first FDA-cleared handheld molecular device, AmpliVue.
Quidel products are used in hospitals, clinical laboratories, doctor's offices, and specialist healthcare screening facilities. The firm also produces and distributes a line of over-the-counter pregnancy tests, branded as RapidVue. The firm is listed on the NASDAQ, where it publicly trades under the stock ticker QDEL.
Start receiving updates on the most recent Quidel Corp price movements when you add QDEL stock to your watchlist to easily monitor real-time changes.